Novotný L - Search Results

1

Simultaneous determination of the new anticancer agent amidox and its metabolites in rat bile and plasma by high-performance liquid chromatography.

Vielnascher E, Romanová D, Novotný L, Szekeres T, Elfort HL, Thalhammer T, Jäger W. Vielnascher E, et al. Among authors: novotny l. J Chromatogr B Biomed Sci Appl. 1997 Aug 29;696(2):267-74. doi: 10.1016/s0378-4347(97)00251-x. J Chromatogr B Biomed Sci Appl. 1997. PMID: 9323547

2

Chromatographic properties of cytosine, cytidine and their synthetic analogues.

Romanová D, Novotný L. Romanová D, et al. Among authors: novotny l. J Chromatogr B Biomed Appl. 1996 Jan 12;675(1):9-15. doi: 10.1016/0378-4347(95)00334-7. J Chromatogr B Biomed Appl. 1996. PMID: 8634774

3

New targets and drugs in cancer chemotherapy.

Szekeres T, Novotny L. Szekeres T, et al. Among authors: novotny l. Med Princ Pract. 2002 Jul-Sep;11(3):117-25. doi: 10.1159/000063243. Med Princ Pract. 2002. PMID: 12138292 Free article. Review.

4

The new inhibitors of ribonucleotide reductase--comparison of some physico-chemical properties.

Romanova D, Vachalkova A, Szekeres T, Elford HL, Novotny L. Romanova D, et al. Among authors: novotny l. J Pharm Biomed Anal. 1997 Apr;15(7):951-6. doi: 10.1016/s0731-7085(96)01937-1. J Pharm Biomed Anal. 1997. PMID: 9160261

5

Iron binding capacity of didox (3,4-dihydroxybenzohydroxamic acid) and amidox (3,4-dihydroxybenzamidoxime) new inhibitors of the enzyme ribonucleotide reductase.

Fritzer-Szekeres M, Novotny L, Vachalkova A, Findenig G, Elford HL, Szekeres T. Fritzer-Szekeres M, et al. Among authors: novotny l. Life Sci. 1997;61(22):2231-7. doi: 10.1016/s0024-3205(97)00925-9. Life Sci. 1997. PMID: 9393942

6

Iron binding capacity of didox (3,4 dihydroxybenzohydroxamic acid) and amidox (3,4 dihydroxybenzamidoxime) two inhibitors of the enzyme ribonucleotide reductase.

Fritzer-Szekeres M, Novotny L, Vachalkova A, Göbl R, Elford HL, Szekeres T. Fritzer-Szekeres M, et al. Among authors: novotny l. Adv Exp Med Biol. 1998;431:599-604. doi: 10.1007/978-1-4615-5381-6_116. Adv Exp Med Biol. 1998. PMID: 9598136

7

Enhanced effects of adriamycin by combination with a new ribonucleotide reductase inhibitor, trimidox, in murine leukemia.

Fritzer-Szekeres M, Novotny L, Romanova D, Göbl R, Sedlak J, Vachalkova A, Rauko P, Elford HL, Szekeres T. Fritzer-Szekeres M, et al. Among authors: novotny l. Life Sci. 1998;63(7):545-52. doi: 10.1016/s0024-3205(98)00305-1. Life Sci. 1998. PMID: 9718080

8

Liquid chromatographic-mass spectrometric determination of celecoxib in plasma using single-ion monitoring and its use in clinical pharmacokinetics.

Abdel-Hamid M, Novotny L, Hamza H. Abdel-Hamid M, et al. Among authors: novotny l. J Chromatogr B Biomed Sci Appl. 2001 Apr 5;753(2):401-8. doi: 10.1016/s0378-4347(00)00574-0. J Chromatogr B Biomed Sci Appl. 2001. PMID: 11334356

9

Benzamide riboside, a recent inhibitor of inosine 5'-monophosphate dehydrogenase induces transferrin receptors in cancer cells.

Szekeres T, Sedlak J, Novotny L. Szekeres T, et al. Among authors: novotny l. Curr Med Chem. 2002 Apr;9(7):759-64. doi: 10.2174/0929867024606911. Curr Med Chem. 2002. PMID: 11966439 Review.

10

Iron binding capacity of trimidox (3,4,5-trihydroxybenzamidoxime), a new inhibitor of the enzyme ribonucleotide reductase.

Szekeres T, Vielnascher E, Novotny L, Vachalkova A, Fritzer M, Findenig G, Göbl R, Elford HL, Goldenberg H. Szekeres T, et al. Among authors: novotny l. Eur J Clin Chem Clin Biochem. 1995 Nov;33(11):785-9. doi: 10.1515/cclm.1995.33.11.785. Eur J Clin Chem Clin Biochem. 1995. PMID: 8620054

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

425 results

Search Page

Filters